Neurolixis Inc. has been awarded a new research grant by the Rett Syndrome Research Trust (RSRT) to advance development of NLX-101, a promising clinical-phase candidate for treatment of Rett syndrome. The grant is the second that Neurolixis has received from the RSRT and will support Chemistry, Manufacturing, and Controls (CMC) studies, preparation of clinical protocols and filing an Investigational New Drug (IND) application for a clinical trial in Rett syndrome patients.
Rett syndrome is a rare and devastating neurological disorder which affects 1 in 10,000 females and for which there is no approved treatment. NLX-101 has shown marked activity in transgenic mouse models of Rett syndrome and has been awarded Orphan Drug designation for this indication in both the USA and in the European Union.
Read the full Neurolixis press release: 
